| abstract |
The invention relates to a compound of the formula (I) wherein A1 and R1, R2, R3, R4 and R5 have the meanings defined in the description and in the claims, which are preferential inhibitors of cysteine protease cathepsin, in particular cysteine protease cathepsin S or L, making them useful as medications, particularly in the treatment of diabetes, abdominal aortic aneurysm, peripheral arterial diseases or diabetic nephropathy. |